Free Trial
NASDAQ:MEIP

MEI Pharma (MEIP) Stock Price, News & Analysis

MEI Pharma logo
$4.22 -0.06 (-1.29%)
As of 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MEI Pharma Stock (NASDAQ:MEIP)

Key Stats

Today's Range
$4.08
$4.45
50-Day Range
$2.36
$6.86
52-Week Range
$1.46
$9.00
Volume
274,506 shs
Average Volume
434,499 shs
Market Capitalization
$138.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

MEI Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

MEIP MarketRank™: 

MEI Pharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 865th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for MEI Pharma.

  • Earnings Growth

    Earnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MEI Pharma is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MEI Pharma is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MEI Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MEI Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    40.00% of the float of MEI Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    MEI Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MEI Pharma has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MEI Pharma does not currently pay a dividend.

  • Dividend Growth

    MEI Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    40.00% of the float of MEI Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    MEI Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MEI Pharma has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MEI Pharma has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for MEI Pharma this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MEI Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.12% of the stock of MEI Pharma is held by insiders.

  • Percentage Held by Institutions

    52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MEI Pharma's insider trading history.
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MEIP Stock News Headlines

MEI Pharma Secures Loan Agreement with BitGo Prime
MEI Pharma Welcomes New Board Member Joshua Riezman
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
MEI Pharma’s Strategic Shift with Litecoin Treasury
See More Headlines

MEIP Stock Analysis - Frequently Asked Questions

MEI Pharma's stock was trading at $2.46 at the start of the year. Since then, MEIP stock has increased by 73.0% and is now trading at $4.2550.

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Shares of MEI Pharma reverse split on Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

MEI Pharma's top institutional shareholders include Rangeley Capital LLC (0.03%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III.
View institutional ownership trends
.

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
9/05/2025
Next Earnings (Estimated)
9/18/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
CIK
1262104
Employees
100
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
($4.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$17.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-77.00%
Return on Assets
-64.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.78
Quick Ratio
16.78

Sales & Book Value

Annual Sales
$65.30 million
Price / Sales
2.15
Cash Flow
$5.62 per share
Price / Cash Flow
0.76
Book Value
$4.96 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
32,840,000
Free Float
31,813,000
Market Cap
$140.23 million
Optionable
Optionable
Beta
0.38

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MEIP) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners